New hope for older lymphoma patients: targeted therapy after chemo may wipe out remaining cancer cells
NCT ID NCT06828991
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study is for people aged 70 and older with a type of blood cancer called DLBCL. After standard chemo, some patients still have tiny traces of cancer DNA in their blood. This trial gives those patients an extra treatment called mosunetuzumab to try to clear that DNA and improve long-term disease control. The study will also check how safe and tolerable the treatment is for older adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wilmot Cancer Institute
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.